Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology

Funding will help advance development of company’s Myotonic Dystrophy therapy

Valencia and Barcelona, Spain, and Paris, France, July 23, 2020 – Arthex Biotech (ARTHEx), a preclinical stage life sciences company focused on the development of the next generation antisense RNA therapies for the treatment of Myotonic Dystrophy Type 1 (DM1), today announces it has closed a funding round of €4.25 million ($4.9M). This round completes an initial seed round of €2.7 million ($3.1M) brought by Invivo and CDTI-Innvierte in December 2019 and in June 2020 respectively. The total funds raised by Arthex since inception are now €6.95 million ($8M).

pdf iconWith the new funding provided by Advent France Biotechnology (AFB) and Invivo Ventures, Arthex can ensure that its therapy will be first-in-human trial ready by 2022; on completion of the ongoing optimization of the drug candidate and subsequent preclinical regulatory studies.

Arthex Team in Valencia

FIPSE

Investors and Venture Capitals health innovation projects

March 2018:

The “Fundación para la Innvación y la Prospectiva en Salud en España” (FIPSE), presents to Investors and Venture Capitals health innovation projects of great impact and path, among which is the project of ARTHEx biotech S.L.

Fundación para la Innvación y la Prospectiva en Salud en España